At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Maintenance with lower doses of lenalidomide and dexamethasoneprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
In Brief
A Phase 3 clinical trial evaluating Maintenance with lower doses of lenalidomide and dexamethasone for Multiple Myeloma. Completed, enrolled 120 participants across 13 sites.
Detailed Summary
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM. The second one is to evaluate the efficacy of the treatment in response rate terms. Otherwise this study wants to evaluate the safety and tolerability of the treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesSpain
CollaboratorsCelgene Corporation
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2007
Primary CompletionDec 2008
Study CompletionJul 2013
TodayJul 2026
First PostedMay 30, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2008
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.1 years ago
Interventions
Maintenance with lower doses of lenalidomide and dexamethasoneprocedure
After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance